Malignant Pleural Mesothelioma: Recent Advances in Diagnosis, Molecular Characterization, Predictive Markers and Treatment

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, which arises from pleural mesothelial cells of the pleura. It is strictly related to asbestos exposure with a latency time of around 20 to 50 years. The global incidence of MPM has continuously risen along with the widespread industrial use of asbestos. MPM is associated with an extremely poor prognosis, considering that a median survival of less than 1 year and a 5-year survival rate of less than 10% are commonly reported. Several aspects of mesothelioma treatment are discussed, in particular, regarding the extent and best type of surgery, radiotherapy, and the role of neoadjuvant or adjuvant treatment.

Recent progress in research and clinical practice has demonstrated evidence relating to molecular pathogenesis and perspectives on potential therapeutic approaches leading to promising treatment, such as immunotherapy, which could be a favorable option for patients with advanced diseases.

This Special Issue is designated to be a comprehensive review of the state-of-the-art advances in scientific research on mesothelioma, including the pathogenesis, diagnosis, and management of MPM, including, but not limited to:

• Diagnosis: histological and molecular characteristics;
• Radiology and tumor response;
• Oncological management;
• Surgery;
• Innovations in radiotherapy;
• Molecular alterations;
• Targeted agents;
• Cellular therapies;
• Prognostic factors;
• Further trials of interest and future perspectives.

Dr. Giuseppe Marulli
Dr. Giuseppe Mangiameli
Dr. Emanuele Voulaz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.